New FDA Approval Expands Use of Cemiplimab in NSCLC
The new approval expands use of the PD-1 inhibitor cemiplimab (Libtayo) to patients with advanced non–small cell lung cancer (NSCLC) irrespective of PD-LI expression.
Source: medscape.com
📰 Mirrors Everyday Practice News
Mirrors Everyday Practice News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mirrors Everyday Practice. Real-time updates on events, politics, business and more.